NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The syndicate was led by Claris Ventures and included 2Invest, 3B Future Health Fund and Astellas Venture Management alongside founding investor the CRT Pioneer Fund.

NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.



NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline

Description

Company Information

Related People

Funding Insights

NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information